Cytosorbents (CTSO) Income from Continuing Operations (2010 - 2026)
Cytosorbents' (CTSO) quarterly Income from Continuing Operations came in at 11040000.0 in Q1 2026, down 646.77% YoY from 2019114.05 in Q1 2025, and down 169.79% on a QoQ basis from 4092000.0 in Q4 2025.
Cytosorbents (CTSO) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Cytosorbents (CTSO) has 17 years of Income from Continuing Operations data on file, last reported at 11040000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 646.77% year-over-year to 11040000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43516000.0 (down 892.28% YoY) and the FY2025 annual result came in at 6793000.0, up 24.49% from the prior year.
- Income from Continuing Operations fell to 11040000.0 in Q1 2026, from 4092000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4156000.0 in Q4 2024 to a low of 25213000.0 in Q2 2025.
- A 5-year average of 6826442.41 and a median of 6134851.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 700.76% — and 2024, when it surged 167.74%.
- Tracing CTSO's Income from Continuing Operations over 5 years: stood at 766126.0 in 2022, then slumped by 700.76% to 6134851.0 in 2023, then surged by 167.74% to 4156000.0 in 2024, then sank by 198.46% to 4092000.0 in 2025, then tumbled by 169.79% to 11040000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 11040000.0 (Q1 2026), 4092000.0 (Q4 2025), and 3171000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.51 Bn | 194.91 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 129.96 Bn | 126.48 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 120.18 Bn | 110.96 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.28 Bn | 73.74 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 52.75 Bn | 48.50 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.67 Bn | 32.73 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 34.23 Bn | 32.12 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.46 Bn | 23.14 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.30 Bn | 22.82 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Cytosorbents | 21.99 Mn | 17.58 Mn | 7.05 Mn | -3.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.52 Mn |
| Mar 31, 2026 | -11.04 Mn |
| Dec 31, 2025 | -4.09 Mn |
| Sep 30, 2025 | -3.17 Mn |
| Jun 30, 2025 | -25.21 Mn |
| Mar 31, 2025 | -1.48 Mn |
| Dec 31, 2024 | 4.16 Mn |
| Sep 30, 2024 | -2.77 Mn |
| Jun 30, 2024 | -4.30 Mn |
| Mar 31, 2024 | -6.09 Mn |
| Dec 31, 2023 | -6.13 Mn |
| Sep 30, 2023 | -9.19 Mn |
| Jun 30, 2023 | -6.60 Mn |
| Mar 31, 2023 | -7.32 Mn |
| Dec 31, 2022 | -766,126.00 |
| Sep 30, 2022 | -12.20 Mn |
| Jun 30, 2022 | -10.88 Mn |
| Mar 31, 2022 | -8.97 Mn |
| Dec 31, 2021 | -9.31 Mn |
| Sep 30, 2021 | -6.41 Mn |